{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:16:58Z","timestamp":1775009818336,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/spd7jju2dooy","name":"None to declare","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/spd7jju2dooy","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The clinical use of colistin methanesulphonate (CMS) is limited by potential nephrotoxicity. The selection of an efficient and safe CMS dose for individual patients is complicated by the narrow therapeutic window and high interpatient pharmacokinetic variability. In this study, a simple predictive equation for estimating the plasma concentration of formed colistin in patients with multidrug and extremely drug-resistant gram-negative bacterial infections was developed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The equation was derived from the largest clinical cohort of patients undergoing therapeutic drug monitoring (TDM) of colistin for over 8 years in a tertiary Spanish hospital. All variables associated with C<jats:sub>ss,avg<\/jats:sub> were selected in a multiple linear regression model that was validated in a second cohort of 40 patients. Measured C<jats:sub>ss,avg<\/jats:sub> values were compared with those predicted by our model and a previous published algorithm for critically ill patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 276 patients were enrolled [the mean age was 67.2 (13.7) years, 203 (73.6%)] were male, and the mean (SD) C<jats:sub>ss,avg<\/jats:sub> was 1.12 (0.98) mg\/L. Age, gender, estimated glomerular filtration rate, CMS dose and frequency, and concomitant drugs were included in the model. In the external validation, the previous algorithm appeared to yield more optimized colistin plasma concentrations when all types of C<jats:sub>ss,avg<\/jats:sub> values (high and low) were considered, while our equation yielded a more optimized prediction in the subgroup of patients with low colistin plasma concentrations (C<jats:sub>ss,avg<\/jats:sub> &lt;1.5 mg\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The proposed equation may help clinicians to better use CMS among a wide variety of patients, to maximize efficacy and prevent nephrotoxicity. A further prospective PK study is warranted to externally validate this algorithm.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001216","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:06:38Z","timestamp":1720609598000},"page":"594-602","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["New Predictive Equation for the Estimation of Plasma Concentrations of Formed Colistin in Patients Treated With Colistimethate Sodium for Multidrug-Resistant Gram-Negative Bacterial Infections"],"prefix":"10.1097","volume":"46","author":[{"given":"Sonia","family":"Luque","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"CIBER of Infectious Diseases (CIBERINFEC CB21\/13\/00002 and CB21\/13\/00099), Institute of Health Carlos III, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"CIBER of Infectious Diseases (CIBERINFEC CB21\/13\/00002 and CB21\/13\/00099), Institute of Health Carlos III, Madrid, Spain;"},{"name":"Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Department of Medicine and Life Sciences (MELIS). Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X\u00e8nia","family":"Fern\u00e1ndez-Sala","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Berenguer","sequence":"additional","affiliation":[{"name":"San Jorge University, Faculty of Health Science, Zaragoza, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Colominas-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Department of Medicine and Life Sciences (MELIS). Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Ben\u00edtez-Cano","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Milagro","family":"Montero","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"CIBER of Infectious Diseases (CIBERINFEC CB21\/13\/00002 and CB21\/13\/00099), Institute of Health Carlos III, Madrid, Spain;"},{"name":"Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Department of Medicine and Life Sciences (MELIS). Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Subirana","sequence":"additional","affiliation":[{"name":"CIBER en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain;"},{"name":"Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Prim","sequence":"additional","affiliation":[{"name":"Microbiology Department. Laboratori de Refer\u00e8ncia de Catalunya, Barcelona, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Paricio","sequence":"additional","affiliation":[{"name":"Pharmacy Department. Hospital Municipal de Badalona, Badalona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Pablo","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"CIBER of Infectious Diseases (CIBERINFEC CB21\/13\/00002 and CB21\/13\/00099), Institute of Health Carlos III, Madrid, Spain;"},{"name":"Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Department of Medicine and Life Sciences (MELIS). Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain;"},{"name":"CIBER of Infectious Diseases (CIBERINFEC CB21\/13\/00002 and CB21\/13\/00099), Institute of Health Carlos III, Madrid, Spain;"},{"name":"Department of Medicine and Life Sciences (MELIS). Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol Rev"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"e01367-17","DOI":"10.1128\/AAC.01367-17","article-title":"Pharmacokinetic\/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients","volume":"61","author":"Forrest","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20250603","article-title":"Colixin 1MUI. Polvo para soluci\u00f3n injectable","journal-title":"Ficha t\u00e9cnica"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International SOCIETY for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1469-0691.2011.03667.x","article-title":"Colistin pharmacokinetics: the fog is lifting","volume":"18","author":"Couet","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R11-20250603","first-page":"1644","article-title":"Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria","volume":"26","author":"Kristoffersson","year":"2020","journal-title":"Clin Microbiol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bcpt.13482","article-title":"Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome","volume":"128","author":"Ram","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/cid\/cix1048","article-title":"Dose suggestions for intravenous colistin in pediatric patients: Caution required","volume":"66","author":"Nation","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-4347(01)00326-7","article-title":"A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography","volume":"761","author":"Li","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"025955-16","DOI":"10.1128\/AAC.02595-16","article-title":"Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections","volume":"61","author":"Luque","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12879-016-2117-7","article-title":"Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa","volume":"17","author":"Sorl\u00ed","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","article-title":"Forming inferences about some intraclass correlation coefficients","volume":"1","author":"McGraw","year":"1996","journal-title":"Psychol Methods"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/ph14090903","article-title":"Population pharmacokinetics of colistin methanesulfonate sodium and colistin in critically ill patients: a systematic review","volume":"14","author":"Zabidi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/jac\/dkac145","article-title":"Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis","volume":"77","author":"Margalit","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkh167","article-title":"Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate","volume":"53","author":"Li","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijantimicag.2013.04.018","article-title":"Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii","volume":"42","author":"Luque","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","article-title":"A review on colistin nephrotoxicity","volume":"71","author":"Ordooei Javan","year":"2015","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:06:29Z","timestamp":1748970389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001216","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2023-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}